Abu Dhabi backs Kaleido’s $101m series C round

A subsidiary of the Abu Dhabi Investment Authority has joined Fidelity and Rock Springs capital as investors.

Kaleido Biosciences has closed a $101m series C funding round that involved the Abu Dhabi Investment Authority, investment firm Fidelity Management and venture capital company Rock Springs Capital.

The business is a clinical-stage healthcare company that focuses on microbiome research. It has raised a total of $166m in funding to date.


Supporting articles

Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.